CORDIS
EU research results

CORDIS
English EN

Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions

Project information

Grant agreement ID: 831434

Status

Ongoing project

  • Start date

    1 September 2019

  • End date

    31 August 2026

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 80 803 177,75

  • EU contribution

    € 40 273 191,50

Coordinated by:

FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD

Spain

Objective

3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions, SMEs, and 8 major pharmaceutical companies, teamed to study a fundamental issue in medicine: the mechanisms of response and non-response to therapies, the major aim of 3TR, both within single disease entities and across diseases, where molecular stratification may identify shared disease taxonomies. The molecular identification of groups of patients to whom a drug will benefit, will allow focusing on those who are drug orphan. Harmonization of data from existing academy or industry-sponsored studies will identify biomarkers to inform a new collection. Specimens of diseased tissues, blood, stools, and other fluids will be obtained in a de novo observational prospective trial with standard of care medication prior, during and after first or second line of treatment. Because the studies will be at different phases of progression, a carrousel model of work was designed for input and output of data to be continuously analysed, and interpreted, to inform those measurements to be undertaken and allow cross-validation of results. The 3TR team will elucidate the role of the microbiome, genetics and regulatory genomic features in disease progression. The working aims of 3TR are: 1) establish a centralized data management platform; 2) perform comprehensive molecular and clinical characterisation of a prospective patient cohort; 3) establish integrated analysis of all data using advanced bioinformatics/statistical and modelling methods; 4) identify sets of predictive biomarkers of response/non-response to therapies; 5) improve the competitiveness of European industry and support development of novel solutions. 3TR will sustain beyond the project end the samples and its knowledge base. 3TR will challenge and revolutionize the conventional single-disease based approach with important implications in future disease treatment.

Programme(s)

H2020-EU.3.1.7. - Innovative Medicines Initiative 2 (IMI2)

Topic(s)

IMI2-2018-14-01 - Targeted immune intervention for the management of non-response and relapse

Call for proposal

H2020-JTI-IMI2-2018-14-two-stage

See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD

Address

Avenida Americo Vespucio 15 Edif S2
41092 Sevilla

Spain

Activity type

Research Organisations

EU Contribution

€ 9 876 529,68

Website

Contact the organisation

Participants (68)

THE UNIVERSITY OF MANCHESTER

United Kingdom

EU Contribution

€ 682 941,25

CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL

Germany

EU Contribution

€ 2 700 000

UNIVERSITY OF LEICESTER

United Kingdom

EU Contribution

€ 523 897,95

EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH

Germany

EU Contribution

€ 1 917 499,43

FUNDACIO CENTRE DE REGULACIO GENOMICA

Spain

EU Contribution

€ 1 665 250

EUROPEAN RESPIRATORY SOCIETY

Switzerland

EU Contribution

€ 361 390,08

FONDAZIONE IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO

Italy

EU Contribution

€ 815 450

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

Netherlands

EU Contribution

€ 717 221,25

ACADEMISCH ZIEKENHUIS GRONINGEN

Netherlands

EU Contribution

€ 120 875

ALACRIS THERANOSTICS GMBH

Germany

EU Contribution

€ 106 250

ATRYS HEALTH, SA

Spain

EU Contribution

€ 237 562,50

AZIENDA OSPEDALE UNIVERSITA PADOVA

Italy

EU Contribution

€ 277 003,50

AZIENDA OSPEDALIERO-UNIVERSITARIA ANNA MEYER

Italy

EU Contribution

€ 146 350

UNIVERSITAIR ZIEKENHUIS GENT

Belgium

EU Contribution

€ 141 508

REGION HOVEDSTADEN

Denmark

EU Contribution

€ 201 780

CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY

France

EU Contribution

€ 825 030,63

UNIVERSITY OF GLASGOW

United Kingdom

EU Contribution

€ 201 000

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany

EU Contribution

€ 541 266,25

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

EU Contribution

€ 287 500

CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Spain

EU Contribution

€ 1 573 843,06

CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P.

Spain

EU Contribution

€ 201 512,74

Deutsches Rheuma-Forschungszentrum Berlin

Germany

EU Contribution

€ 229 595

EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING

Belgium

EU Contribution

€ 70 416,25

EUROPEAN LUNG FOUNDATION

United Kingdom

EU Contribution

€ 110 675

GENOS DOO ZA VJESTACENJE I ANALIZU

Croatia

EU Contribution

€ 106 501,56

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 241 798,96

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 125 000

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES

Portugal

EU Contribution

€ 290 996,25

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 584 499,25

LUPUS EUROPE

United Kingdom

EU Contribution

€ 78 750

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 565 627,50

MEDIZINISCHE HOCHSCHULE HANNOVER

Germany

EU Contribution

€ 285 965

OREBRO UNIVERSITY

Sweden

EU Contribution

€ 893 122,25

OWLSTONE MEDICAL LIMITED

United Kingdom

EU Contribution

€ 139 500

PHILIPPS UNIVERSITAET MARBURG

Germany

EU Contribution

€ 201 565

QUEEN MARY UNIVERSITY OF LONDON

United Kingdom

EU Contribution

€ 2 320 291,36

SERVICIO ANDALUZ DE SALUD

Spain

EU Contribution

€ 1 429 125

SERVICIO MADRILENO DE SALUD

Spain

EU Contribution

€ 387 450

SIP SERVICE S.R.L.

Italy

EU Contribution

€ 201 500

SOCIETE DE PNEUMOLOGIE DE LANGUE FRANCAISE

France

EU Contribution

€ 196 425

STICHTING VUMC

Netherlands

EU Contribution

€ 836 688,75

TECHNISCHE UNIVERSITAET DRESDEN

Germany

EU Contribution

€ 192 500

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 1 170 877,75

THE QUEEN'S UNIVERSITY OF BELFAST

United Kingdom

EU Contribution

€ 161 201,50

UNIVERSITA DEGLI STUDI DI CATANIA

Italy

EU Contribution

€ 145 302,50

UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO

Italy

EU Contribution

€ 294 944,75

UNIVERSITA DEGLI STUDI DI CAGLIARI

Italy

EU Contribution

€ 294 924,76

UNIVERSITA DEGLI STUDI DI GENOVA

Italy

EU Contribution

€ 236 249,38

UNIVERSITA DI PISA

Italy

EU Contribution

€ 292 500

UNIVERSITAT BASEL

Switzerland

EU Contribution

€ 489 568,75

CLINIQUES UNIVERSITAIRES SAINT-LUC

Belgium

EU Contribution

€ 354 942,75

UNIVERSITE DE BRETAGNE OCCIDENTALE

France

EU Contribution

€ 328 000

UNIVERSITEIT HASSELT

Belgium

EU Contribution

€ 247 825

UNIVERSITETET I BERGEN

Norway

EU Contribution

€ 209 617,50

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Ireland

EU Contribution

€ 343 955,31

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 560 011,25

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 890 500

UNIVERSITY OF SOUTHAMPTON

United Kingdom

EU Contribution

€ 201 498,10

UNIVERSYTET MEDYCZNY W LODZI.

Poland

EU Contribution

€ 80 600

VIB

Belgium

EU Contribution

€ 361 018,75

SANOFI-AVENTIS DEUTSCHLAND GMBH

Germany

JANSSEN PHARMACEUTICA NV

Belgium

TAKEDA DEVELOPMENT CENTRE EUROPE LTD

United Kingdom

ASTRAZENECA AB

Sweden

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

United Kingdom

NOVARTIS PHARMA AG

Switzerland

PFIZER LIMITED

United Kingdom

F. HOFFMANN-LA ROCHE AG

Switzerland

Project information

Grant agreement ID: 831434

Status

Ongoing project

  • Start date

    1 September 2019

  • End date

    31 August 2026

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 80 803 177,75

  • EU contribution

    € 40 273 191,50

Coordinated by:

FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD

Spain

Download

PDF XML

Last update: 24 February 2020

Record number: 224791